Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 401-410 of 603 for hematology

Edit search filters
  1. Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients with Myelofibrosis

    Scottsdale/Phoenix, AZ

  3. XmAb18968 (CD3-CD38) In Relapsed Or Refractory Acute Leukemia And T Cell Lymphoblastic Leukemia

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  4. A Study To Evaluate The Effectiveness And Safety Of Panzyga In Patients With Chronic Lymphocytic Leukemia

    Rochester, MN

  5. Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

    Rochester, MN

  6. A Study To Evaluate The Effectiveness And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With Clinical High-Risk Multiple Myeloma

    Scottsdale/Phoenix, AZ

  7. Long-Term Study Of Participants Previously With Ciltacabtagene Autoleucel

    Scottsdale/Phoenix, AZ, Rochester, MN

  8. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib And Dexamethasone (PVd) Or Daratumumab, Pomalidomide And Dexamethasone (DPd) In Participants With Relapsed And Lenalidomide-Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  9. FT516 In Subjects With Advanced Hematologic Malignancies

    Scottsdale/Phoenix, AZ

  10. Daratumumab Retreatment In Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV)

    Rochester, MN

.

Mayo Clinic Footer